Five-day courses of subcutaneous IL-2, administered every 4 weeks safely expanded Treg populations, suppressed monocytes inflammatory markers, and reduced plasma inflammatory cytokines and chemokines in the enrolled AD participants [29]. The gene discussed is IL2; the disease is Alzheimer disease.